UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Actions of angiotensin II on the heart

Authors
Timothy W Smith, MD, PhD
James P Morgan, MD, PhD
Section Editor
Wilson S Colucci, MD
Deputy Editor
Susan B Yeon, MD, JD, FACC

INTRODUCTION

The renin-angiotensin system is a classic endocrine system, and angiotensin II is the primary effector hormone that is secreted in response to physiologic stimuli. However, there is now general agreement that there are complete local renin-angiotensin systems existing entirely within organs or tissues, which function in an autocrine or paracrine fashion [1]. Aldosterone and angiotensin converting enzyme (ACE) are also produced by the failing heart, in proportion to the severity of heart failure [2,3]. (See "Pathophysiology of heart failure: Neurohumoral adaptations".)

Synthesis of angiotensin II — Angiotensin II is an oligopeptide of eight amino acids, formed from its original precursor, angiotensinogen, by a series of two enzymatic cleavages.

Angiotensinogen is released into the circulation by the liver. Renin, produced by the kidney, in response to glomerular hypoperfusion, catalyzes cleavage of angiotensinogen to angiotensin I, a decapeptide.

Angiotensin I is in turn cleaved by ACE to produce the octapeptide angiotensin II. The concentration of ACE is highest in the lung and it had been thought that most angiotensin II formation occurred in the pulmonary circulation. It is now clear, however, that ACE is produced in the vascular endothelium of many tissues; thus, angiotensin II can be synthesized at a variety of sites, including the kidney, vascular endothelium, adrenal gland, and brain. In addition, alternative enzymatic pathways not involving ACE may contribute to angiotensin II production. Human heart chymase may be one such enzyme but its clinical significance remains uncertain. (See 'Alternate pathways of angiotensin II production' below.)

Angiotensin II binds to its specific receptors and exerts its effects in the brain, kidney, adrenal, vascular wall, and the heart.

                   

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Mon Nov 02 00:00:00 GMT+00:00 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. van Kats JP, Danser AH, van Meegen JR, et al. Angiotensin production by the heart: a quantitative study in pigs with the use of radiolabeled angiotensin infusions. Circulation 1998; 98:73.
  2. Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation 2001; 103:72.
  3. Silvestre JS, Heymes C, Oubénaïssa A, et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999; 99:2694.
  4. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87:E1.
  5. Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002; 417:822.
  6. Boehm M, Nabel EG. Angiotensin-converting enzyme 2--a new cardiac regulator. N Engl J Med 2002; 347:1795.
  7. Danser AH, Schalekamp MA, Bax WA, et al. Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation 1995; 92:1387.
  8. Ueda S, Meredith PA, Morton JJ, et al. ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans. Circulation 1998; 98:2148.
  9. Cicoira M, Zanolla L, Rossi A, et al. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol 2001; 37:1808.
  10. Murphey LJ, Gainer JV, Vaughan DE, Brown NJ. Angiotensin-converting enzyme insertion/deletion polymorphism modulates the human in vivo metabolism of bradykinin. Circulation 2000; 102:829.
  11. Pinto YM, van Gilst WH, Kingma JH, Schunkert H. Deletion-type allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilation after anterior myocardial infarction. Captopril and Thrombolysis Study Investigators. J Am Coll Cardiol 1995; 25:1622.
  12. Oosterga M, Voors AA, de Kam PJ, et al. Plasma angiotensin-converting enzyme activity and left ventricular dilation after myocardial infarction. Circulation 1997; 95:2607.
  13. Schunkert H, Hense HW, Holmer SR, et al. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N Engl J Med 1994; 330:1634.
  14. Celentano A, Mancini FP, Crivaro M, et al. Cardiovascular risk factors, angiotensin-converting enzyme gene I/D polymorphism, and left ventricular mass in systemic hypertension. Am J Cardiol 1999; 83:1196.
  15. Tesson F, Dufour C, Moolman JC, et al. The influence of the angiotensin I converting enzyme genotype in familial hypertrophic cardiomyopathy varies with the disease gene mutation. J Mol Cell Cardiol 1997; 29:831.
  16. Montgomery HE, Clarkson P, Dollery CM, et al. Association of angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training. Circulation 1997; 96:741.
  17. Andersson B, Sylvén C. The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure. J Am Coll Cardiol 1996; 28:162.
  18. McNamara DM, Holubkov R, Janosko K, et al. Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 2001; 103:1644.
  19. Fernández-Solà J, Nicolás JM, Oriola J, et al. Angiotensin-converting enzyme gene polymorphism is associated with vulnerability to alcoholic cardiomyopathy. Ann Intern Med 2002; 137:321.
  20. Pfohl M, Athanasiadis A, Koch M, et al. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene is associated with coronary artery plaque calcification as assessed by intravascular ultrasound. J Am Coll Cardiol 1998; 31:987.
  21. Pfohl M, Koch M, Prescod S, et al. Angiotensin I-converting enzyme gene polymorphism, coronary artery disease and myocardial infarction. An angiographically controlled study. Eur Heart J 1999; 20:1318.
  22. Cambien F, Poirier O, Lecerf L, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359:641.
  23. Keavney B, McKenzie C, Parish S, et al. Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. International Studies of Infarct Survival (ISIS) Collaborators. Lancet 2000; 355:434.
  24. Lindpaintner K, Pfeffer MA, Kreutz R, et al. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 1995; 332:706.
  25. Ruiz J, Blanché H, Cohen N, et al. Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is strongly associated with coronary heart disease in non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A 1994; 91:3662.
  26. O'Malley JP, Maslen CL, Illingworth DR. Angiotensin-converting enzyme DD genotype and cardiovascular disease in heterozygous familial hypercholesterolemia. Circulation 1998; 97:1780.
  27. Arnett DK, Davis BR, Ford CE, et al. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation 2005; 111:3374.
  28. Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45:205.
  29. Griendling KK, Lassègue B, Alexander RW. Angiotensin receptors and their therapeutic implications. Annu Rev Pharmacol Toxicol 1996; 36:281.
  30. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996; 334:1649.
  31. Tsutsumi K, Saavedra JM. Characterization and development of angiotensin II receptor subtypes (AT1 and AT2) in rat brain. Am J Physiol 1991; 261:R209.
  32. Grady EF, Sechi LA, Griffin CA, et al. Expression of AT2 receptors in the developing rat fetus. J Clin Invest 1991; 88:921.
  33. Malendowicz SL, Ennezat PV, Testa M, et al. Angiotensin II receptor subtypes in the skeletal muscle vasculature of patients with severe congestive heart failure. Circulation 2000; 102:2210.
  34. Senbonmatsu T, Ichihara S, Price E Jr, et al. Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload. J Clin Invest 2000; 106:R25.
  35. Stoll M, Steckelings UM, Paul M, et al. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995; 95:651.
  36. Ford WR, Clanachan AS, Jugdutt BI. Opposite effects of angiotensin AT1 and AT2 receptor antagonists on recovery of mechanical function after ischemia-reperfusion in isolated working rat hearts. Circulation 1996; 94:3087.
  37. Yang BC, Phillips MI, Ambuehl PE, et al. Increase in angiotensin II type 1 receptor expression immediately after ischemia-reperfusion in isolated rat hearts. Circulation 1997; 96:922.
  38. Nickenig G, Harrison DG. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation 2002; 105:393.
  39. Nickenig G, Harrison DG. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: Part II: AT(1) receptor regulation. Circulation 2002; 105:530.
  40. Bauer JH, Reams GP. The angiotensin II type 1 receptor antagonists. A new class of antihypertensive drugs. Arch Intern Med 1995; 155:1361.
  41. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001; 103:904.
  42. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997; 95:1115.
  43. Munger MA, Furniss SM. Angiotensin II receptor blockers: novel therapy for heart failure? Pharmacotherapy 1996; 16:59S.
  44. Pueyo ME, Michel JB. Angiotensin II receptors in endothelial cells. Gen Pharmacol 1997; 29:691.
  45. Dikalova A, Clempus R, Lassègue B, et al. Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation 2005; 112:2668.
  46. Matsuno K, Yamada H, Iwata K, et al. Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation 2005; 112:2677.
  47. Clemson B, Gaul L, Gubin SS, et al. Prejunctional angiotensin II receptors. Facilitation of norepinephrine release in the human forearm. J Clin Invest 1994; 93:684.
  48. Baker KM, Booz GW, Dostal DE. Cardiac actions of angiotensin II: Role of an intracardiac renin-angiotensin system. Annu Rev Physiol 1992; 54:227.
  49. Lindpaintner K, Ganten D. The cardiac renin-angiotensin system. An appraisal of present experimental and clinical evidence. Circ Res 1991; 68:905.
  50. Allen IS, Cohen NM, Dhallan RS, et al. Angiotensin II increases spontaneous contractile frequency and stimulates calcium current in cultured neonatal rat heart myocytes: insights into the underlying biochemical mechanisms. Circ Res 1988; 62:524.
  51. Baker KM, Singer HA. Identification and characterization of guinea pig angiotensin II ventricular and atrial receptors: coupling to inositol phosphate production. Circ Res 1988; 62:896.
  52. Doggrell SA. The effects of atriopeptin and angiotensin on the rat right ventricle. Gen Pharmacol 1989; 20:253.
  53. Holubarsch C, Hasenfuss G, Schmidt-Schweda S, et al. Angiotensin I and II exert inotropic effects in atrial but not in ventricular human myocardium. An in vitro study under physiological experimental conditions. Circulation 1993; 88:1228.
  54. Ikenouchi H, Barry WH, Bridge JH, et al. Effects of angiotensin II on intracellular Ca2+ and pH in isolated beating rabbit hearts and myocytes loaded with the indicator indo-1. J Physiol 1994; 480 ( Pt 2):203.
  55. Nakamura K, Fushimi K, Kouchi H, et al. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation 1998; 98:794.
  56. Linz W, Schölkens BA, Ganten D. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens A 1989; 11:1325.
  57. Baker KM, Aceto JF. Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. Am J Physiol 1990; 259:H610.
  58. Pellieux C, Foletti A, Peduto G, et al. Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2. J Clin Invest 2001; 108:1843.
  59. Sadoshima J, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993; 75:977.
  60. Harrap SB, Dominiczak AF, Fraser R, et al. Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults. Circulation 1996; 93:1148.
  61. Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115:41.
  62. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995.
  63. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000; 105:1605.
  64. Pastore L, Tessitore A, Martinotti S, et al. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation 1999; 100:1646.
  65. Itoh H, Mukoyama M, Pratt RE, et al. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 1993; 91:2268.
  66. Morawietz H, Rueckschloss U, Niemann B, et al. Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation 1999; 100:899.
  67. Li D, Mehta JL. Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation 2000; 101:2889.
  68. Navalkar S, Parthasarathy S, Santanam N, Khan BV. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol 2001; 37:440.
  69. Potter DD, Sobey CG, Tompkins PK, et al. Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation 1998; 98:800.
  70. Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000; 101:1372.
  71. Strawn WB, Chappell MC, Dean RH, et al. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 2000; 101:1586.
  72. Suganuma E, Babaev VR, Motojima M, et al. Angiotensin inhibition decreases progression of advanced atherosclerosis and stabilizes established atherosclerotic plaques. J Am Soc Nephrol 2007; 18:2311.
  73. Lu H, Rateri DL, Feldman DL, et al. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest 2008; 118:984.
  74. Dakik HA, Mahmarian JJ, Verani MS, et al. Association of angiotensin I-converting enzyme gene polymorphism with myocardial ischemia and patency of infarct-related artery in patients with acute myocardial infarction. J Am Coll Cardiol 1997; 29:1468.
  75. Hoshida S, Yamashita N, Kawahara K, et al. Amelioration by quinapril of myocardial infarction induced by coronary occlusion/reperfusion in a rabbit model of atherosclerosis: possible mechanisms. Circulation 1999; 99:434.
  76. Dzau VJ, Gibbons GH, Pratt RE. Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. Hypertension 1991; 18:II100.
  77. Kim S, Izumi Y, Yano M, et al. Angiotensin blockade inhibits activation of mitogen-activated protein kinases in rat balloon-injured artery. Circulation 1998; 97:1731.
  78. Dostal DE, Baker KM. The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Res 1999; 85:643.
  79. Raman VK, Lee YA, Lindpaintner K. The cardiac renin-angiotensin-aldosterone system and hypertensive cardiac hypertrophy. Am J Cardiol 1995; 76:18D.
  80. Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993; 153:937.
  81. Zisman LS, Asano K, Dutcher DL, et al. Differential regulation of cardiac angiotensin converting enzyme binding sites and AT1 receptor density in the failing human heart. Circulation 1998; 98:1735.
  82. Baker KM, Chernin MI, Wixson SK, Aceto JF. Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol 1990; 259:H324.
  83. Asano K, Dutcher DL, Port JD, et al. Selective downregulation of the angiotensin II AT1-receptor subtype in failing human ventricular myocardium. Circulation 1997; 95:1193.
  84. Haywood GA, Gullestad L, Katsuya T, et al. AT1 and AT2 angiotensin receptor gene expression in human heart failure. Circulation 1997; 95:1201.
  85. Silver RB, Reid AC, Mackins CJ, et al. Mast cells: a unique source of renin. Proc Natl Acad Sci U S A 2004; 101:13607.
  86. Mackins CJ, Kano S, Seyedi N, et al. Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusion. J Clin Invest 2006; 116:1063.
  87. Nash DT. Comparative properties of angiotensin-converting enzyme inhibitors: relations with inhibition of tissue angiotensin-converting enzyme and potential clinical implications. Am J Cardiol 1992; 69:26C.
  88. Chandrasekharan UM, Sanker S, Glynias MJ, et al. Angiotensin II-forming activity in a reconstructed ancestral chymase. Science 1996; 271:502.
  89. Urata H, Boehm KD, Philip A, et al. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 1993; 91:1269.
  90. Nishimura H, Hoffmann S, Baltatu O, et al. Angiotensin I converting enzyme and chymase in cardiovascular tissues. Kidney Int Suppl 1996; 55:S18.
  91. Kokkonen JO, Saarinen J, Kovanen PT. Regulation of local angiotensin II formation in the human heart in the presence of interstitial fluid. Inhibition of chymase by protease inhibitors of interstitial fluid and of angiotensin-converting enzyme by Ang-(1-9) formed by heart carboxypeptidase A-like activity. Circulation 1997; 95:1455.
  92. Pfeufer A, Busjahn A, Vergopoulos A, et al. Chymase gene locus is not associated with myocardial infarction and is not linked to heart size or blood pressure. Am J Cardiol 1998; 82:979.
  93. Khan NU, Movahed A. The role of aldosterone and aldosterone-receptor antagonists in heart failure. Rev Cardiovasc Med 2004; 5:71.
  94. Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res 2005; 96:643.